오피니언 공유하기 기사 공유하기 페이스북 X(트위터) 카카오 텔레그램 네이버 밴드 링크복사 https://koreanewdaily.com/news/section_list_all.html?catid=Y 주소가 복사되었습니다.원하는 곳에 붙여넣기 하세요. 취재수첩 환자는 못 버틴다… 봉합 불발시 외국의사 당장 수입해야 전공의 처분 멈추면 의대교수 사직 철회할까… 산적한 변수 전국 곳곳 의대교수 집단사직 현실로… 봉쇄된 '봉합 출구' 전의교협 "진료축소 불가피… 돌아가시는 분 나오겠지만 의사도 사람"
Intellia CEO on Crispr gene-editing treatment, secondary offering Intellia shares jump on positive gene-editing data Intellia has a special request from FDA for their NTLA-2002. Must know this if you hold NTLA. Intellia Stock vs CRISPR Stock: The Winner Is INTELLIA THERAPEUTICS INC BIG SWING | NTLA STOCK Revolutionary CRISPR Therapy Tool | KEY MILESTONE Analysis on Intellia Therapeutics (NTLA) stock Intellia is the leading CRISPR company Revolutionary CRISPR Therapy Tool | Martin Shkreli Analyses Intellia Therapeutics (NTLA) stock Intellia Therapeutics Overview Intellia Therapeutics: MASSIVE Opportunity in CRISPR - $NTLA Full Analysis Intellia, Regeneron complete first systemic delivery of CRISPR in body CSHL Keynote, Dr. David Lebwohl, Intellia Therapeutics Gene Editing Updates | CRISPR, Intellia, and Beam Intellia: NTLA steady performance, well funded, no immediate catalysts - Earnings review, Intellia Therapeutics, Inc NTLA Stock